First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation
Thiruvengadam, S. Poh, C. Lynch, R. Moskowitz, C. Spinner, M. Hutchings, M. Herce, C. G. Phillips, E. Tun, A. Vose, J.
Thiruvengadam, S.
Poh, C.
Lynch, R.
Moskowitz, C.
Spinner, M.
Hutchings, M.
Herce, C. G.
Phillips, E.
Tun, A.
Vose, J.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Thiruvengadam S, Poh C, Lynch R, Moskowitz C, Spinner M, Hutchings M, et al. First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with relapsed/refractory lymphomas: updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation. Blood. 2025 NOV 3;146:155-6.